down arrow

Kiora Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US49721T3095
USD
2.15
0.26 (13.76%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.092.17

52 Week

1.784.18
Valuation
Technical
Day's Volume

CASH

50.56 k

Shareholding (Jun 2025)

FII

8.44%

Held by 4 FIIs

DII

90.84%

Held by 1 DIIs

Promoter

0.00%

How big is Kiora Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Kiora Pharmaceuticals, Inc. has a market capitalization of 8.95 million, with net sales of 0.02 million and a net profit of -12.04 million over the latest four quarters. The company reported shareholder's funds of 25.76 million and total assets of 36.48 million as of Dec 24.

Market Cap: As of Jun 18, Kiora Pharmaceuticals, Inc. has a market capitalization of 8.95 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Kiora Pharmaceuticals reported net sales of 0.02 million and a net profit of -12.04 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 25.76 million and total assets of 36.48 million.

Read More

What does Kiora Pharmaceuticals, Inc. do?

22-Jun-2025

Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing therapeutics and drug delivery systems for eye diseases. It has a market cap of $8.95 million and reported a net profit loss of $2 million as of March 2025.

Overview:<BR>Kiora Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 8.95 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.01 <BR>Return on Equity: -44.68% <BR>Price to Book: 0.38 <BR><BR>Contact Details:<BR>Address: 271 Waverley Oaks Rd Ste 108, WALTHAM MA: 02452-8475 <BR>Tel: 1 781 7889043 <BR>Website: http://www.eyegatepharma.com/

Read More

Who are in the management team of Kiora Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Kiora Pharmaceuticals, Inc. includes Paul Chaney (Independent Chairman), Stephen From (CEO), Steven Boyd, Keith Maher, Morton Goldberg, Thomas Hancock, and Bernard Malfroy-Camine (all Independent Directors). They oversee the company's strategic direction and operations.

As of March 2022, the management team of Kiora Pharmaceuticals, Inc. includes the following individuals:<BR><BR>- Mr. Paul Chaney, Independent Chairman of the Board<BR>- Mr. Stephen From, President, Chief Executive Officer, Director<BR>- Mr. Steven Boyd, Director<BR>- Mr. Keith Maher, Director<BR>- Dr. Morton Goldberg, Independent Director<BR>- Mr. Thomas Hancock, Independent Director<BR>- Dr. Bernard Malfroy-Camine, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Read More

Is Kiora Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of May 9, 2025, Kiora Pharmaceuticals is considered overvalued with a valuation score of -0.8451, despite a high ROCE of 1262.96%, negative P/E ratio, and a 15.86% decline in stock performance over the past year compared to a 10.26% gain in the S&P 500.

As of 9 May 2025, Kiora Pharmaceuticals, Inc. has moved from an attractive valuation grade to one that does not qualify. The company appears to be overvalued given its current financial metrics. Notably, the Price to Book Value stands at 0.40, while the EV to EBITDA is at 1.17. The Return on Capital Employed (ROCE) is exceptionally high at 1262.96%, but this is misleading as the company is loss-making, reflected in its negative P/E ratio and ROE of -44.68%.<BR><BR>In comparison to its peers, Kiora Pharmaceuticals has a valuation score of -0.8451, while SeqLL, Inc. is at -1.5744 and Hoth Therapeutics, Inc. at -1.7844, indicating that Kiora is relatively better positioned among its peers despite not qualifying for a positive valuation. The recent stock performance shows a decline of 15.86% over the past year, contrasting with a 10.26% gain in the S&P 500, reinforcing the notion that the stock is overvalued in the current market context.

Read More

Is Kiora Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 3, 2025, Kiora Pharmaceuticals has a mildly bearish technical trend, indicated by bearish weekly MACD and moving averages, and has significantly underperformed the S&P 500 with a year-to-date return of -19.68%.

As of 3 September 2025, the technical trend for Kiora Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The weekly MACD is bearish, while the monthly MACD shows a mildly bullish stance. The Bollinger Bands indicate a mildly bearish trend on the weekly chart and bearish on the monthly chart. Daily moving averages are bearish, and the KST is bearish weekly but mildly bullish monthly. The Dow Theory reflects a mildly bearish trend on the weekly timeframe with no trend on the monthly. The OBV shows a mildly bullish signal weekly but no trend monthly.<BR><BR>In terms of performance, Kiora has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -19.68% versus the S&P 500's 12.22%, and a one-year return of -26.78% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven primarily by bearish signals in the weekly MACD and moving averages.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 9 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.92

stock-summary
Return on Equity

-47.46%

stock-summary
Price to Book

0.42

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-23.21%
0%
-23.21%
6 Months
-44.87%
0%
-44.87%
1 Year
-37.68%
0%
-37.68%
2 Years
-56.17%
0%
-56.17%
3 Years
-43.12%
0%
-43.12%
4 Years
-99.52%
0%
-99.52%
5 Years
-99.84%
0%
-99.84%

Kiora Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Kiora Pharmaceuticals, Inc. technically bullish or bearish?

As of 3 September 2025, the technical trend for Kiora Pharmaceuticals, Inc. has changed from bearish to mildly bearish. The weekly MACD is bearish, while the monthly MACD shows a mildly bullish stance. The Bollinger Bands indicate a mildly bearish trend on the weekly chart and bearish on the monthly chart. Daily moving averages are bearish, and the KST is bearish weekly but mildly bullish monthly. The Dow Theory reflects a mildly bearish trend on the weekly timeframe with no trend on the monthly. The OBV shows a mildly bullish signal weekly but no trend monthly. In terms of performance, Kiora has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -19.68% versus the S&P 500's 12.22%, and a one-year return of -26.78% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bearish, driven primarily by bearish signals in the wee...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-6.27%
EBIT to Interest (avg)
-7.32
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.01
Sales to Capital Employed (avg)
0.42
Tax Ratio
22.18%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
47.57%
ROCE (avg)
35.43%
ROE (avg)
3.98%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.40
EV to EBIT
1.16
EV to EBITDA
1.17
EV to Capital Employed
14.66
EV to Sales
-14.66
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1262.96%
ROE (Latest)
-44.68%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Jun 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 2 Schemes (0.71%)

Foreign Institutions

Held by 4 Foreign Institutions (8.44%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 15.38% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.20",
          "val2": "-2.40",
          "chgp": "8.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.10",
          "val2": "-0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.20",
          "val2": "-2.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-121,232.60%",
          "chgp": "12,123.26%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 128.80% vs 8.09% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "16.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2.70",
          "val2": "-8.60",
          "chgp": "131.40%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.20",
          "val2": "-3.90",
          "chgp": "69.23%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "3.60",
          "val2": "-12.50",
          "chgp": "128.80%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "164.50%",
          "val2": "0.00%",
          "chgp": "16.45%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-2.20
-2.40
8.33%
Interest
0.00
0.00
Exceptional Items
-0.10
-0.10
Consolidate Net Profit
-2.20
-2.20
Operating Profit Margin (Excl OI)
0.00%
-121,232.60%
12,123.26%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 0.00% vs 15.38% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
16.00
0.00
Operating Profit (PBDIT) excl Other Income
2.70
-8.60
131.40%
Interest
0.00
0.00
Exceptional Items
-1.20
-3.90
69.23%
Consolidate Net Profit
3.60
-12.50
128.80%
Operating Profit Margin (Excl OI)
164.50%
0.00%
16.45%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 128.80% vs 8.09% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Kiora Pharmaceuticals, Inc. stock-summary
stock-summary
Kiora Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The Company is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.
Company Coordinates stock-summary
Company Details
271 Waverley Oaks Rd Ste 108 , WALTHAM MA : 02452-8475
stock-summary
Tel: 1 781 7889043
stock-summary
http://www.eyegatepharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."